Biomedicines MDPI’s Post

📖 Dive into this #Fridayread and learn how CosMx was used to unveil gene sets linked to treatment response in ulcerative colitis 👉https://bit.ly/3THFViP Scientists from University of California, San Francisco explore how anti-integrin therapy impacts lymphocyte trafficking in ulcerative colitis. Through the lens of single-cell spatial-omics, they delve into cellular networks involving mononuclear phagocytes and fibroblasts describing a spatial atlas for colitis. #singlecellspatial #inflammation #ulcerativecolitis

The article "Base-editing mutagenesis maps alleles to tune human T cell functions" in Nature describes using CRISPR base-editing to map gene functions in details, and identify mutations that enhance or inhibit T cell activity. The study provides valuable insights that could address the limitations of current immunotherapies and identify new drug targets for various diseases, including autoimmune disorders and cancer. Read the full article here: https://buff.ly/4fSqpLu #Biotech #Science #GeneEditing #Article

Roles of H3K4 methylation in biology and disease The protein complexes catalyzing the mono-, di-, and trimethylation and demethylation of H3 lysine 4 (H3K4), as well as those that read these modifications, are essential for differentiation and development. More specifically, trimethylated H3K4 (H3K4me3) plays critical roles in regulating gene expression, as well as transcriptional memory and consistency. Recent studies have indicated that the roles of H3K4me3 in gene expression may be different from what was originally thought. Somatic alterations in genes regulating the methylation and demethylation of H3K4 are common in cancer. #sciencenewshighlights #ScienceMission https://lnkd.in/g79xEc9T https://lnkd.in/gHwVmcmF

📚 In this Friday read, we spotlight a study published in Nature Communications aimed at increasing the efficacy of CAR T therapy by combining it with STING agonists. Researchers used the nCounter platform to analyze gene expression, revealing increased T cell activation and infiltration into tumors 👉https://lnkd.in/dM9a_SBM This combination improved survival and tumor control in models, presenting a promising strategy for enhancing CAR T therapy efficacy. #CARTherapy #CancerResearch #FridayRead

Timothy J. Taxter, M.D. presenting now our new Endometrial prognosticator. Here we show how we divide NSMP into a new high risk subtype that is characterized by low levels of expression of ESR1 and high genomic fragmentation. Session PO.CL01.10 - Predictive Biomarkers 5 , Section 43 6416 / 28 - Early stage endometrioid endometrial cancer recurrence risk stratification using a machine learning RNA-seq gene expression signature                          #Tempus #AACR24

Is Gene Editing the Best Approach to a Cancer Vaccine? At #RAADfest 2024, Dr. Ronjon Nag presented groundbreaking advancements in gene editing and cancer treatment. To watch the full presentation, go here: https://lnkd.in/gD3TC-YZ #CancerResearch #GeneEditing #Innovation #HealthRevolution #ClinicalTrials #StanfordResearch #MedicalBreakthroughs #TeamScience #Biotech #Longevity #ReverseAging

Unlocking the secrets of missense mutations! Scientists from the #UniversityofCalifornia deploy SEUSS, a perturb-seq method, to interpret challenging single-gene missense mutations in the RUNX1 gene (associated with myelogenous leukemia). 🎯 The study demonstrates the potential of targeting protein interactions to map phenotypes caused by missense mutations, which could reshape our understanding of genetic variations in leukemia. Quick Read: https://lnkd.in/gPGzexMp #bioinformatics #cancerresearch #perturbseq #scrnaseq #singlecell #transcriptomics #runx1 #mutations #leukemia #machinelearning #ai #sciencenews

This week at #ASGCT2024 Creyon Bio’s CMO, David Dimmock, MD, will present clinical data showing how we used our AI- and data-driven platform to rapidly engineer an antisense oligonucleotide investigational therapy for treatment of an ultra-rare disease. This underscores the potential of AI to create new safe and active oligonucleotide therapeutic candidates with significantly improved efficiency for common and rare diseases targeting the genetic underpinning of disease. https://lnkd.in/dezfE_V9 American Society of Gene & Cell Therapy TNPO2 Foundation

Check out our latest paper and related patent on how to reduce fibrosis in the infarcted heart We are happy that our paper “Pericardial delta like non-canonical NOTCH ligand 1 (Dlk1) augments fibrosis in the heart through epithelial to mesenchymal transition” finally has been published in “Clinical and Translational Medicine”.   Heart fibrosis after myocardial infarction lowers heart function and is a huge problem worldwide accounting for high mortality and low quality of life. Our data suggest that targeting Dlk1 or one of its downstream effectors- Itgb8 represent new strategies for reducing heart fibrosis in MI patients for which we have also obtained a patent (WO2022/268644 A1).   Thanks to a grant from the Innovation Foundation Denmark, we are now trying to further test this treatment strategy by developing Dlk1 and Itgb8 based gene therapy.   Link to article: https://lnkd.in/dQCiBb5e and thanks to all collaborators for their contributions and congratulation to everybody involved.

Is Gene Editing the Best Approach to a Cancer Vaccine? At #RAADfest 2024, Dr. Ronjon Nag presented groundbreaking advancements in gene editing and cancer treatment. To watch the full presentation, go here: https://lnkd.in/gxmgYNZ3 #CancerResearch #GeneEditing #Innovation #HealthRevolution #ClinicalTrials #StanfordResearch #MedicalBreakthroughs #TeamScience #Biotech #Longevity #ReverseAging